戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d expression of the antisickling hemoglobin, hemoglobin F.
2 n was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly
3                                      Greater hemoglobin F and erythropoietin each independently predi
4    Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible
5 the association equilibrium constant between hemoglobins F and A lessened progressively.
6 red to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively.
7                   The hemolysis-lowering and hemoglobin F-augmenting effects of hydroxyurea may exert
8 ing the production of cells containing fetal hemoglobin (F cells).
9                                              Hemoglobin F correlated positively with erythropoietin e
10 protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested a
11 e the mechanisms that increase the levels of hemoglobin F (HbF) in the blood of patients with severe
12 sion, inflammatory pathways, upregulation of hemoglobin F, hemoglobin polymerization and sickling, co
13                       Hydroxyurea and higher hemoglobin F improve the clinical course and survival in
14                   In conclusion, increase in hemoglobin F in sickle cell disease may be associated wi
15  producing a modest increase in the level of hemoglobin F in symptomatic patients with this disease s
16 , despite the significantly higher levels of hemoglobin F in the former, suggesting that efforts dire
17                             Tetrameric fetal hemoglobin F in the liganded state was found to dissocia
18  This may in part reflect the lower level of hemoglobin F in this condition compared with other forms
19 agnosis included age less than 2 years and a hemoglobin F level of less than 10%.
20 otypes showed earlier presentation and lower hemoglobin F levels in patients with c-Cbl mutations.
21  receiving hydroxyurea; they also had higher hemoglobin F (P < .001) and erythropoietin (P = .012) le
22  low dose is frequently prescribed to induce hemoglobin F production in patients with sickle cell and
23 sease was treated with hydroxyurea to induce hemoglobin F production since 2007 without incident.
24          Greater levels of erythropoietin or hemoglobin F were independently associated with higher t

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。